A synthetic four–amino-acid peptide (sequence AEDG) modelled on Epithalamin, a pineal-gland extract studied in Russian gerontology. It is researched for aging, sleep-rhythm, telomere, and cellular-stress biology — and is best known for lab claims that it switches on telomerase, the enzyme that maintains the protective caps on chromosomes. The reality is more modest: most of what is known comes from cell, animal, and review-level work over roughly 25 years, with only limited and older human data. It is not approved as a drug, and the FDA lists epitalon among bulk substances that may pose significant safety risks in compounding. Everything below the identity line is an educational research scaffold — not validated medicine.
Epitalon (Ala-Glu-Asp-Gly, AEDG; MW 390.35 Da) is a synthetic pineal tetrapeptide derived from the amino-acid composition of Epithalamin. Reported mechanisms cluster around telomerase/telomere modulation, a direct influence on pineal melatonin synthesis (AANAT / pCREB), antioxidant and mitochondrial effects, modulation of IL-2 mRNA and thymocyte mitogenic activity, and gene-expression/epigenetic regulation — almost entirely in vitro and in vivo. The strongest human signal is an older elderly-cohort study reporting normalization of the night-time melatonin rhythm in subjects with pineal insufficiency. Human pharmacokinetics — half-life, Cmax, Tmax, bioavailability — are not established; every dose ladder below is a research model, not prescribing.
Epitalon (CAS 307297-39-8, C₁₄H₂₂N₄O₉, MW 390.35, PubChem CID 219042; UNII O65P17785G) is a short bioregulator peptide rather than a single-receptor ligand. Khavinson 2003 reported induction of telomerase activity and telomere elongation in human somatic cells; a 2025 Biogerontology paper reported increased telomere length in human cell lines via telomerase upregulation or ALT activity. A 2020 study proposes an epigenetic (histone-H1-interaction) mechanism for AEDG regulation of gene expression and protein synthesis during neurogenesis. The evidence base is dominated by the St. Petersburg / Khavinson bioregulator program, with thin independent modern replication and no robust human PK or registered interventional RCT. Overall GRADE for any clinical longevity use: LOW to VERY LOW.
Epitalon occupies an unusual position — a large mechanistic and Russian-origin bioregulator literature footprint, a handful of older human biomarker signals, and an almost complete absence of modern, independently replicated, placebo-controlled human trials. Every efficacy figure below is preclinical, biomarker-level, or practice-pattern; the regulatory and evidence-grade facts are the ones to weigh most heavily.
Epitalon doesn't act on one switch — it is described as a small signalling peptide nudging several aging-related systems at once. Its most famous proposed effect is on telomeres, the protective caps on chromosomes: in lab cells it has been reported to switch on telomerase, the enzyme that lengthens them. It is also tied to the pineal gland and night-time melatonin, to antioxidant effects inside cells, and to changes in which genes are turned on. Nearly all of this is from cells and animals — treat it as a promising mechanism story, not proven human biology.
Six mechanistically linked arms, almost all preclinical. First — telomerase/telomere biology: induction of telomerase activity and telomere elongation in human somatic cells. Second — pineal/melatonin rhythm: modulation of pineal functional state and increased night melatonin in elderly subjects with pineal insufficiency. Third — gene-expression / epigenetic regulation, with a proposed histone-H1 interaction altering transcription during neurogenesis. Fourth — antioxidant / mitochondrial stress modulation. Fifth — geroprotective / lifespan signals in animal models (heterogeneous). Sixth — anti-carcinogenesis signals in rodents, balanced against the theoretical caution that telomerase activation raises in cancer biology.
Epitalon is a short bioregulator with no canonical receptor and no established human Ki/EC50. The telomere arm is the most studied: a 2025 Biogerontology report describes telomere elongation through telomerase upregulation or alternative lengthening of telomeres (ALT) in human cell lines. The 2025 IJMS review catalogues a direct influence on melatonin synthesis (AANAT / pCREB in pinealocytes), modulation of IL-2 mRNA and thymocyte mitogenicity, and effects on AChE/BuChE — while stressing the mechanism remains unverified and physico-chemical/structural data are limited. Primate data show decreased basal glucose/insulin and increased basal night melatonin in old monkeys. Independent modern replication is thin; overall translation to clinical longevity endpoints is unproven.
This is a speculative hypothesis engine — not approved dosing. Every ladder, threshold, and titration rule below is a research-model scaffold layered on top of (1) practice-pattern ranges (commonly 100–500 µg/day in short cycles) and (2) the absence of any validated human pharmacokinetics. No standardized, trial-validated human dose ladder exists for Epitalon, and the FDA flags compounding safety risks including immunogenicity, aggregation, and peptide-related impurities. The structure mirrors how clinicians titrate biologics and is intended as a base for protocol critique and research design — not prescribing. Each protocol is built to the same skeleton: starting model, escalation cadence, dose ladder, maintenance target, cycle structure, reconstitution math, monitoring overlay, and explicit evidence grade.
100 µg SC once daily, given human PK/safety uncertainty and first-exposure unknown tolerance. Inject SC (abdomen), rotate sites.250 µg/day; do not escalate on a fixed schedule and do not auto-escalate if no measurable endpoint changes. There is no validated response biomarker to titrate toward.100 µg → 250 µg → 500 µg/day. Cap selectable doses at 500 µg/day unless explicitly flagged research-only; >500 µg/day has no strong PK/safety basis.250–500 µg/day across the cycle. Maintenance is the in-cycle dose, not an indefinite daily regimen.10–20 days on, then an optional 4–8 week washout before any repeat course. The short-course pattern reflects bioregulator tradition, not evidence.100–250 µg/day IM. As with SC, start at the low band given unknown tolerance.100 µg → 250 µg → 500 µg/day; cap at 500 µg/day unless flagged research-only.250 µg/day across the cycle.10–20 days, optional washout as for SC.100 µg/day equivalent. Dose equivalence to injectable cannot be assumed because nasal bioavailability is unknown.100 µg → 250 µg/day equivalent, with a hard caveat that the "equivalent" is nominal, not bioavailability-corrected.100–250 µg/day equivalent across the cycle.10–20 days.The engine anchors every protocol to three daily-dose tiers. The weight-band table below is calculator/scaffold logic only — Epitalon is dosed as a fixed µg/day course in practice, not by body weight, so the µg/kg column is an interpolation convenience, not a clinical formula. All values are evidence grade D/P.
| Band | Research-model dose | ≈ µg/kg/day @70 kg | Rationale | Grade |
|---|---|---|---|---|
| Low | 100 µg/day | 1.4 µg/kg | Conservative exploratory band; first-exposure / sensitive individuals. Not clinically validated. | P/D |
| Standard | 250 µg/day | 3.6 µg/kg | Typical practice-pattern band; no approved label. | D |
| High | 500 µg/day | 7.1 µg/kg | Upper research/practice band; higher uncertainty, not validated. | D |
| Do-not-extrapolate | >500 µg/day | >7.1 µg/kg | No strong PK/safety basis; flag as off-protocol research-only. | D |
| Body weight | Low ≈1.5 µg/kg | Standard ≈3.5 µg/kg | High ≈7 µg/kg |
|---|---|---|---|
| ~55 kg | 83 µg | 193 µg | 385 µg |
| ~65 kg | 98 µg | 228 µg | 455 µg |
| ~75 kg | 113 µg | 263 µg | 525 µg* |
| ~85 kg | 128 µg | 298 µg | 595 µg* |
| ~95 kg | 143 µg | 333 µg | 665 µg* |
| ~105 kg | 158 µg | 368 µg | 735 µg* |
*Cap displayed/selectable "high" doses at 500 µg/day unless higher values are clearly marked research-only and not validated. Weight bands are interpolated for scaffold logic; no formal µg/kg formula or trial basis exists. No pediatric dosing exists — pediatric use is off-protocol by default.
Generic heuristics mirroring how clinicians titrate cautiously — clearly marked unvalidated for Epitalon. Because there is no validated response biomarker, escalation is conservative and dose-chasing is discouraged. Hard stops reflect regulatory/ethical caution and the telomerase/tumour-biology uncertainty, not observed Epitalon events.
| Trigger | Action | Rationale | Grade |
|---|---|---|---|
| First exposure / unknown tolerance | Start low (100 µg/day) | Human PK/safety uncertainty. | D |
| Headache, dizziness, insomnia, vivid dreams, daytime sedation | Hold or reduce | Possible circadian / CNS sensitivity. | D |
| Injection-site swelling, rash, systemic allergic symptoms | Hard stop & medical evaluation | Immunogenicity / impurity concern. | D |
| Active malignancy, suspicious lesion, unexplained weight loss / night sweats | Avoid / hard stop | Telomerase & tumour-biology uncertainty. | D |
| Pregnancy / lactation | Avoid | No safety data. | D |
| Competitive athlete under testing | Avoid unless formally cleared | WADA / S0 prohibited-risk context. | D |
| Abnormal CBC/CMP or inflammatory reaction | Hold & evaluate | Non-specific safety monitoring. | D |
| No measurable endpoint after a cycle | Do not auto-escalate | No validated response biomarker. | D |
Special populations — renal, hepatic, elderly, pregnancy: no PK/PD data stratified by eGFR or Child-Pugh exists for Epitalon. Conservative default: avoid outside IRB-approved protocols.
No Epitalon trial defines a biomarker-based endpoint, numeric target, or MCID. Each measure below is explicitly flagged validated_for_Epitalon = false — except the melatonin rhythm, which is mechanistic but not at clinical-validation level. The engine drives any escalation/hold off direction-of-change and tolerability, not off an Epitalon-specific cut-off.
| Biomarker / measure | Purpose | Notes | Validated? |
|---|---|---|---|
| Sleep diary / actigraphy | Circadian response signal | Useful L2 tracking; not an efficacy marker. | No |
| Morning fatigue / daytime sleepiness | Tolerability / rhythm signal | Track adverse effect vs benefit. | No |
| Melatonin rhythm / DLMO | Mechanistic research endpoint | Older human signal exists; mechanistic, not routine clinical validation. | Partial / mech. |
| CBC with differential | General safety | Baseline + post-cycle screen. | No |
| CMP / liver / kidney | General safety | Especially if multiple compounds used. | No |
| hs-CRP | Inflammation context | Not Epitalon-specific. | No |
| Fasting glucose / insulin / HbA1c | Metabolic context | Primate data suggest metabolic effects; not a validated human monitor. | No |
| Telomere length testing | Research curiosity | High variability; do not use as therapeutic proof. | No |
| Standard cancer screening | Risk governance | Use standard-of-care, not peptide-specific surveillance. | Not specific |
Architecture note: store each biomarker with a validated_for_Epitalon boolean (currently false across the board, melatonin rhythm = mechanistic). Flip to true only when an actual registered Epitalon trial supports it.
For reference only. Not medical dosing advice. Epitalon is dosed in micrograms (µg) — small draw volumes mean precision matters. Verify peptide purity (≥98% HPLC), sterility, endotoxin limits, identity (MS), and storage. Only use product from a licensed / verified source for any injection protocol.
Epitalon is frequently combined with other longevity and bioregulator peptides. No published controlled study has evaluated Epitalon in combination with any other agent in humans — every stack below is a concept based on mechanistic or traditional-pairing logic, not clinical-trial data. No pharmacokinetic or pharmacodynamic interaction data exist. The default engine rule is to keep each component conservative and avoid simultaneous high-end dosing of multiple agents.
| Component | Role | Status |
|---|---|---|
| Epitalon | Pineal/melatonin-rhythm modulation | Limited human signal (B/D) |
| Melatonin | Exogenous circadian hormone | Approved supplement (varies) |
| Combination | Circadian support | No combination data (D) |
| Component | Role | Status |
|---|---|---|
| Epitalon | Pineal / circadian bioregulator | Preclinical + limited human (P/D) |
| Thymalin | Thymic / immune bioregulator | Not FDA-approved (D) |
| Combination | Aging / immune pairing | No controlled data (D) |
| Component | Role | Status |
|---|---|---|
| Epitalon | Telomere / circadian signalling | Preclinical + limited human (P/D) |
| GHK-Cu | ECM remodeling · gene expression | Cosmetic-approved · small clinical (B/C) |
| Combination | Longevity / repair concept | No combination data (D/P) |
| Component | Role | Status |
|---|---|---|
| Epitalon | Antioxidant / mitochondrial signal | Preclinical (P) |
| NAD+ / precursors | Cellular energy / redox | Supplement evidence varies |
| Combination | Cellular-aging concept | No combination data (D/P) |
Cancer / proliferative-signalling caution. Avoid stacking Epitalon with other growth, telomerase, GH/IGF-1, or proliferative-signalling agents in anyone with active malignancy, unexplained abnormal cancer screening, premalignant lesions, or strong cancer-risk concerns. This is a risk-governance rule grounded in the unresolved tension between rodent chemoprevention signals and telomerase-driven proliferation concerns — not a proven Epitalon-specific contraindication. If a user profile flags active malignancy, the engine should suppress telomerase/proliferative stacks and label the combination "discouraged."
Epitalon does not have a modern, large, independently replicated human safety database. The FDA specifically flags potential risks in compounded epitalon products related to immunogenicity, aggregation, peptide-related impurities, and a lack of sufficient route-specific human safety information. Older human biomarker work reported no major problems, but it is far too limited for a safety conclusion, and there is no long-term human data. As with all gray-market peptides, product quality is a dominant practical hazard.
Given the absence of robust human data, all contraindications are precautionary — based on theoretical mechanism and regulatory caution, not observed Epitalon events.
| Condition / factor | Risk level | Applies to | Rationale |
|---|---|---|---|
| Active cancer | Avoid | All routes | Telomerase / proliferation uncertainty; no data to establish safety. |
| Recent cancer remission without oncology clearance | Avoid | All routes | Risk-governance concern pending clearance. |
| Unexplained mass, weight loss, night sweats | Avoid | All routes | Do not mask diagnostic workup. |
| Pregnancy | Avoid | All routes | No safety data. |
| Lactation | Avoid | All routes | No safety data. |
| Pediatric use | Avoid | All routes | No safety data; off-protocol by default. |
| Autoimmune disease | Caution | Systemic | Immune-modulation uncertainty. |
| History of severe allergy to injectables | Caution | Injectable | Peptide / impurity reaction risk. |
| Competitive tested athlete | Avoid | All routes | WADA S0 prohibited-risk — not approved for human therapeutic use. |
| Severe uncontrolled insomnia / bipolar mania risk | Caution | All routes | Circadian / sleep-disruption concern. |
| Use of multiple experimental peptides | Caution | All routes | Attribution and additive safety risk. |
| Unverified "research-chemical" product | Avoid | All routes | Sterility / endotoxin / identity risk; require HPLC ≥98%, sterility, endotoxin, MS identity. |
Epitalon has a large mechanistic and Russian-origin bioregulator footprint, a handful of older human biomarker signals, and a near-absence of modern, independently replicated, placebo-controlled human trials. The honest summary: an experimental pineal tetrapeptide with preclinical and limited human circadian-biomarker evidence; longevity, telomere, and dosing claims remain unproven.
"Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells" (Bull. Exp. Biol. Med., PMID 12937682) — the foundational in-vitro report behind Epitalon's telomere positioning, and the most-cited single finding in its literature.
Reported increased telomere length in human cell lines through telomerase upregulation or alternative-lengthening-of-telomeres (ALT) activity (Biogerontology, PMID 40908429) — a modern follow-on to the 2003 telomerase work. Still cell-level; not a human outcome.
"Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in elderly people" (Adv. Gerontol., PMID 17969590) — reported modulation of pineal functional state and increased night melatonin in subjects with pineal insufficiency. The strongest human signal, but limited and older.
"Pineal peptides restore the age-related disturbances in hormonal functions..." in old monkeys (Exp. Gerontol., PMID 15664732) — decreased basal glucose/insulin and increased basal night melatonin. Suggestive endocrine signal of unclear human relevance.
"AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism" (Molecules, PMC7037223) — increased neurogenic markers in human cells with a proposed histone-mediated mechanism.
"Epitalon protects against post-ovulatory aging-related damage in oocytes via modulating mitochondrial activity and ROS levels" (Aging, PMC9037278) — an antioxidant/mitochondrial signal in a cell-aging model.
"Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice" (Biogerontology, PMID 14501183) — reported no change in food consumption, body weight, or mean lifespan in that model. An important counterweight to the longevity narrative.
"The role of pineal gland in breast cancer development" (Crit. Rev. Oncol. Hematol., PMID 12791421) — describes pineal peptides including Epitalon inhibiting mammary carcinogenesis in rodents. Not an approved oncology-prevention strategy, and balanced against telomerase caution.
"Peptides of pineal gland and thymus prolong human life" (Neuro Endocrinol. Lett., PMID 14523363) — an older gerontology program claiming geroprotective effects of pineal/thymic peptides (Epithalamin/Thymalin, not clean Epitalon-only), with limited independent confirmation.
"Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties" (Int. J. Mol. Sci., PMID 40141333) catalogues 25 years of in vitro/in vivo/in silico work — telomerase, melatonin synthesis (AANAT/pCREB), antioxidant/mitochondrial, IL-2 and thymocyte effects — while stressing the mechanism remains unverified and physico-chemical data are limited.
Overall evidence strength: LOW to VERY LOW for clinical use. Epitalon has a large mechanistic and Russian-origin bioregulator literature footprint, but modern, independently replicated, placebo-controlled human trials with a standardized product, defined route/dose, PK, adverse-event capture, and clinically meaningful endpoints are missing. Search-visible ClinicalTrials.gov results did not confirm a robust Epitalon-only interventional trial base. The strongest defensible page wording remains: "an experimental pineal tetrapeptide with preclinical and limited human circadian-biomarker evidence; longevity, telomere, and dosing claims remain unproven." This is precisely why the dosing engine above is framed as a speculative hypothesis layer, not a guideline.
| Parameter | Epitalon / Epithalon | Thymalin | Pinealon | GHK-Cu |
|---|---|---|---|---|
| Primary positioning | Longevity / circadian / telomere research | Immune aging / thymic bioregulator | Neuro / cognitive bioregulator | Skin / wound / hair / copper peptide |
| Mechanism class | Pineal tetrapeptide; telomerase / melatonin / gene-expression signalling | Thymic peptide extract / bioregulator | Short neuropeptide bioregulator | Copper-binding tripeptide |
| Evidence tier | P / C / D (limited human biomarker) | D / C | P / D | P / C / D |
| Common routes | SC · IM · intranasal · oral (research) | Injectable (Russian-origin literature) | Injectable / research | Topical · injectable (practice) |
| Regulatory status | Not FDA-approved; compounding safety-risk list | Not FDA-approved | Not FDA-approved | Not FDA-approved for systemic longevity use |